Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5‑HT3 receptor antagonist presented as an oral dosage form for systemic use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult and pediatric patients. It is indicated for both acute and delayed phases of nausea and vomiting.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical product to hospitals, oncology centres, and pharmacies worldwide, ensuring quality and regulatory compliance throughout the supply chain.

Ondansetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting.

Chemotherapy‑induced nausea and vomiting: reduces incidence and severity in cancer patients. Radiation‑induced nausea and vomiting: prevents symptoms during radiotherapy. Postoperative nausea and vomiting: helps control nausea after surgery.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhoea - Abdominal pain

Serious or Rare Side Effects: - QT interval prolongation - Cardiac arrhythmias - Severe allergic reactions (anaphylaxis) - Serotonin syndrome - Hepatic enzyme elevation - Vision disturbances

Precautions should be taken when prescribing ondansetron. - Cardiac risk assessment: evaluate QT interval before initiating therapy. - Electrolyte monitoring: correct hypokalaemia and hypomagnesaemia to reduce arrhythmia risk. - Concomitant QT‑prolonging drugs: avoid or monitor closely. - Hepatic impairment: use with caution and consider dose adjustment. - Renal impairment: monitor renal function and adjust if necessary. - Store at room temperature: keep in original container, protect from moisture and light.

Ondansetron may interact with several medications.

Major Interactions (Avoid): - Other QT‑prolonging agents (e.g., quinidine, haloperidol): increased risk of serious arrhythmias. - Apomorphine: can cause severe hypotension. - Serotonergic drugs (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Aprepitant: may increase ondansetron concentrations, requiring dose review.